FDA Expands Eligibility for COVID-19 Booster Dose to 16- and 17-Year-Olds

Last Updated: Dec 10, 2021

On December 10, the U.S. Food and Drug Administration amended the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 Vaccine, authorizing the use of a single booster dose for administration to individuals 16 and 17 years of age at least six months after completion of primary vaccination with the Pfizer-BioNTech COVID-19 Vaccine.